Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?

Jardin, Fabrice; Tilly, Hervé

doi:10.1016/s2666-7568(22)00150-7

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-free regimens, targeted therapies such as Bruton’s tyrosine kinase inhibitors, immunotherapies such as lenalidomide, and bispecific antibodies are novel options that may offer promising strategies in older patients ( Table 2 ) [ 60 , 61 , 62 ]. The safety and effectiveness of chemotherapy-free strategies, such as ibrutinib, rituximab, and lenalidomide, have been tested as first-line options in frail or unfit patients aged ≥75 years [ 63 ].…”

Section: New Novel and Chemotherapy-free Regimensmentioning

confidence: 99%

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Yamasaki

2024

Hematology Reports

View full text Add to dashboard Cite

Most patients with diffuse large B-cell lymphoma (DLBCL) are >65 years of age, with the number of patients expected to increase in the coming years. A comprehensive geriatric assessment that carefully evaluates fitness status and comorbidities is essential for selecting the appropriate treatment intensity. Although generally healthy patients or those <80 years of age may benefit from standard immunochemotherapy, unfit/frail patients or patients >80 years old may require reduced-intensity chemotherapy or less-toxic drugs. Some new drugs are currently being tested as single or combined agents for first-line treatment, aiming to improve the outcomes of conventional chemotherapy. This review systematically collates and discusses the outcomes associated with the use of immunochemotherapy in older patients with DLBCL, as well as considering the impact of full-dose immunochemotherapy on quality of life in older and frail patients, summarizing the rationale for reduced dosing in the older population, and presenting recommendations for selecting patients likely to benefit from reduced dosing. If preliminary efficacy and safety data are confirmed in future clinical trials, non-chemotherapy-based immunotherapy approaches could become an alternative potentially curative option in frail patients and those >80 years of age with DLBCL.

show abstract

Section: New Novel and Chemotherapy-free Regimensmentioning

confidence: 99%

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Yamasaki

2024

Hematology Reports

View full text Add to dashboard Cite

show abstract

“…When some patients cannot tolerate anthracyclines, they can be replaced by etoposide or gemcitabine 6,7 . However, chemo‐free therapy is also a beneficial option for frail patients 8 . To further optimize geriatric assessment, researchers devised the simplified geriatric assessment (sGA) and Elderly Prognostic Index (EPI) to predict overall survival (OS), progression‐free survival (PFS), and early mortality 9–11 .…”

Section: Introductionmentioning

confidence: 99%

“… 6 , 7 However, chemo‐free therapy is also a beneficial option for frail patients. 8 To further optimize geriatric assessment, researchers devised the simplified geriatric assessment (sGA) and Elderly Prognostic Index (EPI) to predict overall survival (OS), progression‐free survival (PFS), and early mortality. 9 , 10 , 11 These easy‐to‐use tools offer benefits in the identification of distinct risk categories and assist in treatment selection.…”

Section: Introductionmentioning

confidence: 99%

Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma

Yun,

Bai,

Feng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Geriatric assessment can aid in optimizing treatment strategies and supportive interventions for older patients with diffuse large B‐cell lymphoma (DLBCL). Fondazione Italiana Linformi has recently introduced novel geriatric assessment tools, simplified Geriatric Assessment (sGA) and Elderly Prognostic Index (EPI), aimed at tailoring the treatment and predicting the outcomes for older patients with DLBCL. The objectives of this study are the validation and possible modification of the sGA and EPI in China. In the study, both sGA and EPI demonstrated the predictive capabilities for overall survival (OS) and early mortality (both p < 0.05) in older individuals with DLBCL. Albumin, serving as an independent predictive biomarker for OS (p = 0.006), was utilized to adjust the measurements, resulting in the establishment of sGA‐A and EPI‐A. The sGA‐A effectively addressed the shortcomings of the sGA and EPI in predicting PFS and surpassed them in predicting OS and early mortality. Nevertheless, there is insufficient evidence to support the use of sGA and EPI as treatment guidance tools. In conclusion, the modified sGA‐A model proved to be a successful instrument for geriatric assessment of older patients with DLBCL.

show abstract

Curative intent therapy for DLBCL in the elderly

Tucci,

Masina,

Luminari

2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?

Cited by 4 publications

References 11 publications

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma

Curative intent therapy for DLBCL in the elderly

Contact Info

Product

Resources

About